Examining the Frequency of the JAK2 (V617F) Mutation in Patients with Myeloproliferative Diseases in North Eastern Iran and the Effect of Treatment Intervention | Zendy

Mojila Nasseri | Zendy; Fatemeh Keyfi | Zendy; Raheleh Rahbarian | Zendy; Majid Rajabian | Zendy; Mohammad Reza Abbaszadegan | Zendy

Open Access

Examining the Frequency of the JAK2 (V617F) Mutation in Patients with Myeloproliferative Diseases in North Eastern Iran and the Effect of Treatment Intervention

Author(s) -

Mojila Nasseri,

Fatemeh Keyfi,

Raheleh Rahbarian,

Majid Rajabian,

Mohammad Reza Abbaszadegan

Publication year - 2020

Publication title -

reports of biochemistry and molecular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.467

H-Index - 8

ISSN - 2322-3480

DOI - 10.29252/rbmb.9.2.188

Subject(s) - essential thrombocythemia , polycythemia vera , myeloproliferative disorders , myelofibrosis , medicine , mutation , janus kinase 2 , myeloid leukemia , jak2 v617f , population , mutation frequency , myeloid , gastroenterology , immunology , genetics , biology , bone marrow , gene , receptor , environmental health

Janus kinase 2 ( JAK2 ) is a tyrosine kinase located in the cytoplasm that plays a critical role in the signal transduction of cytokines and growth hormones. The conversion of valine to phenylalanine at the polypeptide position 617 results in the JAK2 (V617F) mutation, which often found in patients with myeloproliferative neoplasms (MPNs). As a result of this mutation, JAK2 is constitutively activated leading to uncontrolled cell growth. The present study aimed to investigate the frequency and relationship of the JAK2 (V617F) mutation in a population of patients with MPNs in Iran.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research